Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Prins

Showing results (91-100 of 153) with videos related to

Pageof 16
Sort By:
The Lancet. Healthy Longevity|September 13, 2022
Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort studyInge M W Verberk, Malika B Laarhuis, Karlijn A van den Bosch, et al.
Human Brain Mapping|March 31, 2018
A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive declineSander C J Verfaillie, Rosalinde E R Slot, Ellen Dicks, et al.
Annals of Neurology|September 10, 2018
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological ChangesInge M W Verberk, Rosalinde E Slot, Sander C J Verfaillie, et al.
Neurobiology of Aging|September 11, 2019
Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regionsNick A Weaver, Thomas Doeven, Frederik Barkhof, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 10, 2022
Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of raceGanesh M Babulal, Sanne Franzen, Erin L Abner, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2021
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteriaSanne Franzen, Jade Emily Smith, Esther van den Berg, et al.
Neurology|May 12, 2004
Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetricsN D Prins, E C W van Straaten, E J van Dijk, et al.
Alzheimer'S Research & Therapy|January 9, 2020
Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCIJolien F Leijenaar, Geert Jan Groeneveld, Erica S Klaassen, et al.
Alzheimer'S Research & Therapy|October 13, 2018
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a studyPhilip Scheltens, Merja Hallikainen, Timo Grimmer, et al.
Neurobiology of Aging|October 3, 2021
BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe projectKarlijn A van den Bosch, Inge M W Verberk, Jarith L Ebenau, et al.
Pageof 16

Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
The Lancet. Healthy Longevity|September 13, 2022
Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort studyInge M W Verberk, Malika B Laarhuis, Karlijn A van den Bosch, et al.
Human Brain Mapping|March 31, 2018
A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive declineSander C J Verfaillie, Rosalinde E R Slot, Ellen Dicks, et al.
Annals of Neurology|September 10, 2018
Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological ChangesInge M W Verberk, Rosalinde E Slot, Sander C J Verfaillie, et al.
Neurobiology of Aging|September 11, 2019
Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regionsNick A Weaver, Thomas Doeven, Frederik Barkhof, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 10, 2022
Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of raceGanesh M Babulal, Sanne Franzen, Erin L Abner, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2021
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteriaSanne Franzen, Jade Emily Smith, Esther van den Berg, et al.
Neurology|May 12, 2004
Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetricsN D Prins, E C W van Straaten, E J van Dijk, et al.
Alzheimer'S Research & Therapy|January 9, 2020
Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCIJolien F Leijenaar, Geert Jan Groeneveld, Erica S Klaassen, et al.
Alzheimer'S Research & Therapy|October 13, 2018
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a studyPhilip Scheltens, Merja Hallikainen, Timo Grimmer, et al.
Neurobiology of Aging|October 3, 2021
BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe projectKarlijn A van den Bosch, Inge M W Verberk, Jarith L Ebenau, et al.
Pageof 16